PFE
Seven years later, and the chart still looks good
Pfizer dropped a fresh update on its CROWN trial, and the headline is basically: LORBRENA keeps hanging on like the last guest at a really good party. The seven-year follow-up in previously untreated ALK-positive advanced or metastatic non-small cell lung cancer showed what Pfizer called the longest progression-free survival reported to date in this setting.
That matters because oncology is a game of time. If a drug can keep cancer from progressing longer than the alternatives, it can become the thing doctors reach for first — and that can turn into durable sales, not just a quick spike and fade.
Why investors should care
LORBRENA (lorlatinib) is one of Pfizer’s more important precision-oncology assets, and long-term data like this is exactly the kind of ammo pharma companies love to bring to the market. It helps with:
- Physician adoption: strong follow-up data can make the drug feel like the safer bet
- Market share: better durability can pressure rivals like XALKORI in this niche
- Lifecycle value: longer efficacy often means a longer commercial runway
The bigger picture
This isn’t a “new drug, new revenue” moment. It’s more like Pfizer just showed the endurance stats on a product it already owns — the pharma equivalent of finding out your marathon runner also had great split times. In a world where every extra month of progression-free survival can move prescribing behavior, this kind of update is the sort of thing that can quietly matter a lot.
Big picture: Pfizer doesn’t need every drug to be a blockbuster overnight. It just needs enough of these slow-burn wins to keep the oncology engine humming.